Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

E.Y. Kim



Author of

  • +

    P2.12 - Poster Session 2 - NSCLC Early Stage (ID 205)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P2.12-017 - Clinical Impact of Dynamic Contrast-Enhanced CT in Stage IA Non-Small Cell Lung Cancer: Net Enhancement is an Independent Predictor of Recurrence. (ID 2501)

      09:30 - 09:30  |  Author(s): E.Y. Kim

      • Abstract

      Background
      Microvessel density is known as a prognostic indicator for patients with solid organ malignancy and the extent of enhancement on CT is positively correlated with the extent of microvessel density. The purpose of this study is to investigate the prognostic significance of dynamic contrast-enhanced (DCE) CT in patients with stage IA non-small cell lung cancer (NSCLC).

      Methods
      From January 2003 through December 2006, we retrospectively enrolled 118 patients (men: women = 67:51; mean age, 58.6 years) with stage IA NSCLC who underwent DCE CT with helical technique (unenhanced images and series of dynamic enhanced images covering primary lung cancer at 30, 60, 90 and 120 seconds and 5 and 10 minutes) after intravenous contrast medium injection and followed by curative surgery. Data were collected on age, pathologic subtype, and size, peak attenuation and net enhancement of primary lung cancer and then correlated with overall, metastasis-free, and recurrence-free survivals that occurred through December 31, 2011.

      Results
      Figure 1In multivariate analysis, net enhancement of primary lung cancer was independently associated with recurrence (hazard ratio [HR] 1.024, P=.013), metastasis (HR 1.027, P=.023), and overall survival (HR 1.025, P=.044). Net enhancement of 80 HU predicted significantly higher risk for the recurrence (P=.028) and metastasis (P=.025) after curative surgery of stage IA lung cancer. The significance of tumor size was proved only in the correlation with recurrence (HR 1.069, P=.038) .

      Conclusion
      Our study confirmed the prognostic significance of net enhancement as an indirect biomarker of tumor angiogenesis for patients with stage IA NSCLC.